---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-26-004488"
form_type: "8-K"
ticker: "EBRCZ"
cik: "0001347123"
company_name: "EBR Systems, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:46:27.274628+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ

## Summary
- Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.
- 41 WiSE implants in Q1 2026, more than double Q4 2025; cumulative 71 commercial implants.
- Added 16 purchase agreements (total 37) and 22 trained physicians (total 55) in Q1.
- 1-for-10 reverse stock split effective April 1; CDI conversion ratio changed to 10:1.
- Management cites strong commercial momentum, expanding site readiness and physician training.

## SEC filing metadata
- accession: 0001214659-26-004488
- form_type: 8-K
- ticker: EBRCZ
- cik: 0001347123
- company_name: EBR Systems, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/0001214659-26-004488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/z482608k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-26-004488
- JSON: https://secwatch.observer/filing/0001214659-26-004488.json
- Plain text: https://secwatch.observer/filing/0001214659-26-004488.txt

## Key facts
- Earnings Releases
  EBR Systems, Inc. reported the first quarter ended March 31, 2026 results: revenue US$2.25M to US$2.36M.
  - Period: the first quarter ended March 31, 2026
  - Revenue: US$2.25M to US$2.36M
  - Result: preliminary results
  source text: in 41 commercial patients during the quarter, bringing total implants across the pilot phase and Limited Market Release to 71 · EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments · The Limited Market Release continued to advance in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/0001214659-26-004488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.